The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in viv
about
Potential role of High mobility group box 1 in hepatocellular carcinomaNovel insights for high mobility group box 1 protein-mediated cellular immune response in sepsis: A systemic reviewModulation of the DNA-binding activity of Saccharomyces cerevisiae MSH2-MSH6 complex by the high-mobility group protein NHP6A, in vitroAntitumor immunity induced after α irradiationInhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond.S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regenerationPDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia.Axonal amphoterin mRNA is regulated by translational control and enhances axon outgrowthStem cell activation in skeletal muscle regeneration.Human muscle satellite cells show age-related differential expression of S100B protein and RAGERAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.Role of HMGB1 in apoptosis-mediated sepsis lethality.Chloroquine improves the response to ischemic muscle injury and increases HMGB1 after arterial ligation.A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway.An advanced glycation end product (AGE)-receptor for AGEs (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein function.Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy.RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.The receptor RAGE: Bridging inflammation and cancerEndogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.HMGB1 is an early and critical mediator in an animal model of uveitis induced by IRBP-specific T cells.Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells.High-mobility group box 1, oxidative stress, and disease.Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer.Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies?Caveolins in rhabdomyosarcomaReceptor for advanced glycation end products (RAGE) and its ligands: focus on spinal cord injury.Investigation of phosphoproteome in RAGE signaling.Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1.5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells.FIP200 is involved in murine pseudomonas infection by regulating HMGB1 intracellular translocationEthyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1-RAGE axis.S100B protein in tissue development, repair and regeneration.RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells.HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases.Receptor for advanced glycation end products contributes to postnatal pulmonary development and adult lung maintenance program in mice.S100 Proteins As an Important Regulator of Macrophage Inflammation.The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo.
P2860
Q26864508-4278CC23-08AB-4392-8159-46823ACE7948Q27001023-D04E6584-308C-4D29-AC0D-529833A90A8FQ27931842-39B88F07-1539-49A4-9AC5-EE74269E62DFQ33891246-CFC754E8-8250-45AC-95B1-CFC722975669Q34043446-83DAD0B7-1314-4775-A21F-CA64BDEA28DBQ34106243-8217F7F6-F9EE-4838-A840-06C2B3839F88Q34140133-0C364ABE-679E-47C6-84FA-9B86DCCDB33FQ34835916-69A42953-A6F1-4CA0-9B14-768777CDBB99Q35307726-AAB18962-DEA7-40AF-A34B-02963847725BQ35547307-D53F8D5F-3242-4A83-BDFF-D075B1D66F19Q35562286-73B14824-5F0C-489B-8C54-46E0205F3BA9Q35963173-1191FC5F-07FF-43A8-8F73-41D83F42A776Q36228722-F5CC776E-1FE2-47C1-9952-F2D7A74CEC3EQ36297374-7F681E73-BD68-4A3D-91FA-5986D8BAEB8BQ36321887-7A877A92-424B-47FF-8A6B-C55009886C1CQ36492859-422319B3-036C-436C-8D71-42040B4A6ED0Q36796758-7F49D91E-BBEB-43CE-A652-9B1D15F13C1EQ37152947-27999A1A-6D22-4EE6-B24F-69FA0450F3F4Q37212720-5A1A02A6-E7A0-4E6D-83DD-05D7A52131EFQ37229916-B5052FD6-D572-4B20-89F1-BE51CD73CFC4Q37644976-4319543B-C4B2-4AD2-990C-F1568B6AB745Q37676466-6FB1FB74-BA70-426F-ACF3-54004A3C2683Q37802381-54D498A2-4560-4575-88B0-BB367797C86DQ37825897-877126C3-EEBE-4329-8A46-D53D4FDD0138Q37825936-DFB0E3DB-1451-429A-B4B0-A9C5FF19A577Q37894860-55D08BA7-7A21-4DF0-919F-0683CB5D7212Q38234624-0B22C420-9AE1-4DE9-8D06-D4F110E2CE8BQ38260264-5AAFE3CF-C787-48C5-A49A-B69B6BAF04B6Q38786090-867EBF9D-ABD4-40EF-8C08-9CEDE011A655Q38968288-4112EDDE-59C3-43FC-8803-E0B0F1B046D5Q38985509-66CC01E2-730F-43BD-9650-31AC90878ADAQ39214419-CC526DFE-537A-401C-9026-E3F0891D5900Q39752451-A988D5A8-4735-406A-8927-F3890505DF80Q39994864-B721EB37-C71D-41C8-A125-45B6446EBAC6Q41243946-012E07E5-F518-4D7C-BE6E-31B38D749F69Q45165504-8398B339-6848-49C0-AA6F-B1A54E0459AAQ49497885-C2A60855-A03B-4A81-9890-C9B6DFC65B63Q55181875-380DB38E-BEA6-4753-8820-A5C7CF35F855Q55259742-DDB64C93-0EC4-4F92-9456-68BD2D0832F7
P2860
The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in viv
description
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artículu científicu espublizáu en 2006
@ast
im März 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/03/24)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/03/24)
@nl
наукова стаття, опублікована в березні 2006
@uk
name
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@ast
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@en
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@nl
type
label
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@ast
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@en
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@nl
prefLabel
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@ast
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@en
The amphoterin (HMGB1)/recepto ...... ults in tumor formation in viv
@nl
P2093
P2860
P50
P356
P1476
The amphoterin (HMGB1)/recepto ...... lts in tumor formation in vivo
@en
P2093
Francesca Riuzzi
Guglielmo Sorci
Rosario Donato
P2860
P304
P356
10.1074/JBC.M509436200
P407
P577
2006-01-09T00:00:00Z